This conference will give you a comprehensive and thorough picture of how small and large molecule products—as well as diagnostics—operate in a world not only governed by PTO and FDA-related laws and regulations, but also against the backdrop of Hatch-Waxman, BPCIA, iconoclast Supreme Court decisions affecting the future life sciences IP, and healthcare reform. The faculty will provide insights and strategies relative to lifecycle management, portfolio strategies, brand optimization, and new product development as well as thoughtful and targeted commentary and in-depth analysis.

WilmerHale Partner Michael Twomey will be speaking on the panel "Impact of PGR, IPR and Other PTO Proceedings on Life Cycle Planning Strategies for Large and Small Molecules."